VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

AACR 2021 | HAMMER: THOR-707, a novel not-alpha IL-2 in advanced/metastatic solid tumors

Filip Janku, MD, PhD, MD Anderson Cancer Center, TX, outlines safety and preliminary anti-tumor activity for THOR-707, a recombinant human IL-2 molecule, currently evaluating as a monotherapy and combined with pembrolizumab in the ongoing HAMMER Phase I/II clinical trial (NCT04009681). In patients with advanced or metastatic solid tumors, THOR-707 has demonstrated encouraging results, with initial efficacy and a tolerable safety profile. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Filip Janku, MD, PhD, has received research support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Astex, Agios, Bicara, Bioxcel Therapeutics, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Merck, Ideaya Biosciences, JS Innophram, Synthorx, Sanofi, SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, FujiFilm Pharmaceuticals, Sotio, Lilly, Puretech Health and Novellus; is or has been on the Scientific Advisory Boards for Bicara, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Petra Pharma, Novellus and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter